RAIDD Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB, IF, ICC, E |
---|---|
Primary Accession | P78560 |
Other Accession | AAB42217, 8738 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | 22 kDa |
Application Notes | RAIDD antibody can be used for detection of RAIDD by Western blot at 0.5 - 1 μg/mL. A 22 kDa band should be detected. Antibody can also be used for immunocytochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL. |
Gene ID | 8738 |
---|---|
Other Names | RAIDD Antibody: MRT34, RAIDD, Death domain-containing protein CRADD, Caspase and RIP adapter with death domain, CASP2 and RIPK1 domain containing adaptor with death domain |
Target/Specificity | RAIDD antibody was raised against a 19 amino acid peptide near the center of human RAIDD. The immunogen is located within amino acids 90 - 140 of RAIDD. |
Reconstitution & Storage | RAIDD antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Precautions | RAIDD Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | CRADD |
---|---|
Synonyms | RAIDD |
Function | Adapter protein that associates with PIDD1 and the caspase CASP2 to form the PIDDosome, a complex that activates CASP2 and triggers apoptosis (PubMed:15073321, PubMed:16652156, PubMed:17159900, PubMed:17289572, PubMed:9044836). Also recruits CASP2 to the TNFR-1 signaling complex through its interaction with RIPK1 and TRADD and may play a role in the tumor necrosis factor-mediated signaling pathway (PubMed:8985253). |
Cellular Location | Cytoplasm {ECO:0000250|UniProtKB:O88843}. Nucleus {ECO:0000250|UniProtKB:O88843} |
Tissue Location | Constitutively expressed in most tissues, with particularly high expression in adult heart, testis, liver, skeletal muscle, fetal liver and kidney. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
RAIDD Antibody: Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain (DD)-containing receptors, TNFR1 and Fas. The death signals are transduced by a group of DD-containing adapter molecules. A novel cell death adapter was recently identified by two independent groups and designated RAIDD (RIP-associated ICH-1/CED-3-homologous protein with DD) and CRADD (caspase and RIP adapter with DD)1, RAIDD contains a DD and a CARD (for caspase recruitment domain) which interact with RIP and caspase, respectively, to transduce death signals1, 3. RAIDD is constitutively expressed in many tissues and mediates apoptosis caused by Fas and TNFR-1.
References
Duan H, Dixit VM. RAIDD is a new 'death' adaptor molecule. Nature 1997;385:86-89
Ahmad M, Srinivasula SM, Wang L, Talanian RV, Litwack G, Fernandes-Alnemri T, Alnemri ES. CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP. Cancer Res 1997 57:615-619
Hofmann K, Bucher P, Tschopp J. The CARD domain: a new apoptotic signalling motif. Trends Biochem Sci 1997;22:155-156 (RD1299)

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.